Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jdermsci.2010.07.012 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Immunotherapy using pullulan-conjugated Der f 2 allergen in canine atopic dermatitis: An anti-inflammatory agent-sparing approach.
Vet Dermatol
December 2024
Zenoaq, Koriyama, Fukushima, Japan.
Background: Allergen immunotherapy is used as aetiological treatment for canine atopic dermatitis (cAD).
Objective: To assess the anti-inflammatory agent-sparing effect over 1 year of immunotherapy using pullulan-conjugated recombinant Der f 2 (rDf2-P).
Animals: Twenty-one privately owned dogs with cAD.
Tralokinumab Treatment in Adult Atopic Dermatitis Patients: 28-Week Evaluation of Clinical Effectiveness, Safety, Serum Proteins and Total IgE Levels.
Allergy
December 2024
National Expertise Center for Atopic Dermatitis, Department of Dermatology and Allergology, University Medical Center Utrecht, Utrecht, The Netherlands.
Introduction And Objectives: Tralokinumab-a biological that specifically targets interleukin-13-is one of the newer advanced systemic treatments for patients with moderate-to-severe atopic dermatitis (AD). Although safety and efficacy have been shown in phase-III clinical trials, daily practice data are needed. Therefore, the aim of this study was to evaluate 28-week safety and effectiveness, serum proteins and total IgE levels in adult AD patients treated with tralokinumab in daily practice.
View Article and Find Full Text PDFDupilumab reduces inflammatory biomarkers in pediatric patients with moderate-to-severe atopic dermatitis.
J Allergy Clin Immunol
August 2024
Sanofi, Madrid, Spain.
Article Synopsis
- Pediatric patients with moderate-to-severe atopic dermatitis (AD) showed elevated inflammatory biomarkers, which dupilumab treatment aimed to reduce.
- In a study involving various age groups, patients received either dupilumab or a placebo, leading to significant reductions in biomarkers such as TARC/CCL17, total IgE, and lactate dehydrogenase (LDH) after 16 weeks.
- The results indicate that dupilumab effectively minimizes inflammation in these patients, reaching levels similar to healthy individuals.
Quantitative and qualitative analysis of stability for 16 serum immunoregulators over 50 freeze-thaw cycles.
Am J Hum Biol
September 2024
Department of Anthropology, Binghamton University, Binghamton, New York, USA.
Objectives: To evaluate the reliability of data from the assay of bio-archived specimens, a 50-freeze-thaw-cycle (FTC) degradation study of fresh sera was conducted to test the stability of 16 immunoregulators.
Methods: Twenty de-identified serum specimens were obtained from volunteers at United Health Services-Wilson Memorial Hospital. Specimens were stored at -20°C and underwent daily 1 h thawing and subsequent freezing for each FTC over 50 consecutive days.
Jianpi Yangxue Qufeng compound alleviates atopic dermatitis via TLR4/MyD88/NF-κB signaling pathway.
Heliyon
January 2024
Department of Dermatology, First Affiliated Hospital of Yunnan University of Chinese Medicine, Kunming 650032, Yunnan, China.
Background: Jianpi Yangxue Qufeng Compound (JPYXQFC) is a Chinese medicine widely used in the clinical treatment of atopic dermatitis (AD) and has a significantly therapeutic effect. However, the mechanism of JPYXQFC in AD has been not understood clearly.
Objective: This study aimed to explore the effect of JPYXQFC on AD model cells and rats by regulating TLR4/MyD88/NF-κB signaling pathway.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!